Pralidoxime--the gold standard of acetylcholinesterase reactivators--reactivation in vitro efficacy
Language English Country Germany Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
21180265
Knihovny.cz E-resources
- MeSH
- Acetylcholinesterase metabolism MeSH
- Antidotes pharmacology MeSH
- Rats MeSH
- Brain metabolism MeSH
- Pralidoxime Compounds pharmacology MeSH
- Cholinesterase Reactivators pharmacology MeSH
- In Vitro Techniques MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Acetylcholinesterase MeSH
- Antidotes MeSH
- pralidoxime MeSH Browser
- Pralidoxime Compounds MeSH
- Cholinesterase Reactivators MeSH
OBJECTIVE: In this work, we aim to summarize the universality of this compound, its reactivation potential when different cholinesterase inhibitors are used. BACKGROUND: Pralidoxime is considered as a gold standard of acetylcholinesterase reactivators--antidotes used in case of nerve agent poisonings. It has been commercially available for many years. However, several studies deem this oxime an old-fashion antidote. METHODS: Pralidoxime was synthesized at our department. The reactivating efficacy was tested on 10% (w/v) rat brain homogenate that had been incubated with appropriate inhibitor for 30 minutes to reach 96% inhibition of AChE. Then, pralidoxime was added for 10 minutes. Measurements were performed at 25 degrees C, pH 8, and 10(-3) and 10(-5) M concentrations of AChE reactivators. The activities of brain AChE were measured by a potentiostatic method. RESULTS: No sufficient reactivation was achieved at the concentration of 10(-5) M, which is a concentration that can be reached after administration of therapeutic doses. At a higher dose (10(-3) M), pralidoxime reactivated AChE inhibited by paraoxon, chlorpyrifos, Russian VX, VX and sarin. CONCLUSION: From the obtained results, it is clear that pralidoxime seems to be a poor reactivator of AChE inhibited by organophosphorous AChE inhibitors and thus cannot be labeled as a universal reactivator (Tab. 1, Fig. 3, Ref. 31).